Cost-effectiveness and accuracy of cervical cancer screening with a high-risk HPV genotyping assay vs a nongenotyping assay in China: an observational cohort study.

Binhua DongLihua ChenWenyu LinYingying SuXiaodan MaoDiling PanGuanyu RuanHuifeng XueYafang KangPeng-Ming Sun

Published in: Cancer cell international (2020)

The PCR-RDB HR-HPV genotyping and Cervista® HR-HPV assay results were consistent. PCR-RDB cotesting possesses optimal cost-effectiveness for cervical cancer screening in China, which has the highest number of cases globally but low screening coverage.

Keyphrases

cervical cancer screening
high throughput
genome wide
healthcare
gene expression
high grade
dna methylation